Welcome to our dedicated page for I-MAB American Depositary Shares news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-MAB American Depositary Shares stock.
I-Mab American Depositary Shares (Nasdaq: IMAB) represent a leading clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel and highly differentiated biologics to treat diseases with unmet medical needs, focusing on cancers and autoimmune disorders. With operations in Rockville, Maryland, and San Diego, California, I-Mab is actively involved in groundbreaking research and innovative drug development.
The company’s pipeline includes several promising candidates:
- Felzartamab (TJ202): A CD38 antibody in Phase III trials for multiple myeloma and autoimmune diseases.
- Eftansomatropin (TJ101): A long-acting human growth hormone that has completed Phase II trials for pediatric growth hormone deficiency.
- Olamkicept (TJ301): An IL-6 blocker in Phase II trials for ulcerative colitis and autoimmune diseases.
- Enoblituzumab: A humanized B7-H3 antibody that has completed Phase I trials for head and neck cancer and other oncology diseases.
- Efineptakin (TJ107): A long-acting recombinant human IL-7 in Phase II trials for glioblastoma multiforme (GBM).
I-Mab's innovative pipeline is driven by its internal R&D strategies, Fast-to-Proof-of-Concept, and Fast-to-Market development, often in collaboration with global partners. Recently, I-Mab announced the divestiture of its Chinese assets and operations, aiming to focus on the U.S. and other international markets. This strategic move included the transfer of its Greater China rights for various assets, potentially generating up to US$80 million based on future milestone achievements.
Notably, the company has entered into a clinical trial collaboration with Bristol Myers Squibb to evaluate givastomig combined with nivolumab and chemotherapy as a first-line treatment for advanced Claudin 18.2-positive gastric and esophageal cancers. I-Mab’s robust development pipeline and strategic global partnerships exemplify its commitment to advancing novel therapies to address critical medical needs.
For the latest updates and detailed information, visit the official website at I-Mab Biopharma.
I-Mab (Nasdaq: IMAB) has been added to the MSCI China All Shares Index, effective May 27, 2021. This inclusion follows the company's recent addition to the NASDAQ Biotechnology Index in December 2020, indicating its growing recognition among global investors. The MSCI China Index includes large and mid-cap Chinese stocks, offering a benchmark for equity exposure. I-Mab aims to progress as a fully integrated global biopharmaceutical entity and is advancing key pipeline products, including felzartamab, lemzoparlimab, and uliledlimab.
I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, announced its participation in several conferences during May 2021. Key events include the HSBC 8th Annual China Conference from May 11-21, the CICC 2021 Healthcare Investment Forum on May 18, the Macquarie D.E.L.T.A.H. China Conference on May 21, and the Morgan Stanley China Summit from May 26-28. Management representatives will include Chairman Dr. Jingwu Zang and CEO Dr. Joan Huaqiong Shen. These conferences aim to provide insights into the company’s novel biologics and clinical pipeline developments.
I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, announced it filed its annual report on Form 20-F for the year ended December 31, 2020, with the SEC on April 28, 2021. This report is accessible via the company's investor relations website and the SEC's site. I-Mab focuses on developing novel biologics in the immuno-oncology field and aims to transition from a clinical-stage to a fully integrated global biopharmaceutical company. The company has over 15 drug candidates in its pipeline and operates globally, including in China and the U.S.
I-Mab (Nasdaq: IMAB) has announced positive topline results from its Phase 2 clinical study of olamkicept for treating active ulcerative colitis (UC). This randomized, double-blind trial showed that patients receiving 600 mg olamkicept biweekly had significantly higher clinical response rates after 12 weeks compared to placebo (p=0.032). Key secondary endpoints, including clinical remission and mucosal healing, were also met (p<0.001). The drug demonstrated a favorable safety profile. I-Mab aims to expand olamkicept's market reach, exploring collaborations in the U.S., Canada, and Europe.
I-Mab (Nasdaq: IMAB) has announced that its abstract on the CD73 antibody, uliledlimab, has been selected for a poster presentation at the 2021 ASCO Annual Meeting scheduled for June 4-8, 2021. This antibody is designed to modulate the tumor microenvironment and enhance anti-tumor responses, particularly when combined with PD-(L)1 inhibitors. Preliminary clinical studies have shown that uliledlimab is safe and well tolerated, demonstrating clinical activity in patients with advanced solid tumors. Further research is ongoing to validate its efficacy.
I-Mab (Nasdaq: IMAB) and ABL Bio (Kosdaq: 298380) announce the dosing of the first patient in a Phase 1 trial for bispecific antibody TJ-L14B/ABL503. This trial aims to assess the safety and efficacy of the antibody in treating locally advanced or metastatic solid tumors (NCT04762641). Developed using ABL's 'Grabody-T' technology, the bispecific antibody targets PD-L1 and engages T-cell activation to enhance antitumor activity while reducing off-tumor toxicity. Initial results suggest improved efficacy over traditional treatments.
I-Mab (Nasdaq: IMAB) announced its participation in several key conferences in April 2021, showcasing its commitment to advancing immuno-oncology therapeutics. Notable events include the 20th Annual Needham Healthcare Conference and the 2021 Haitong Securities Spring Listed Companies Conference, where management presentations by key executives such as Dr. Jingwu Zang and Ms. Leah Liu will take place. The company continues to evolve from a clinical-stage biotech entity to a fully integrated global biopharmaceutical company, with a robust pipeline of over 15 drug candidates.
I-Mab (Nasdaq: IMAB) and ABL Bio, Inc. have received FDA approval for their Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for the bispecific antibody TJ-CD4B/ABL111. This trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of TJ-CD4B/ABL111 in patients with advanced or metastatic solid tumors. The antibody targets Claudin 18.2, enhancing immune response specifically at tumor sites while minimizing side effects. Both companies are optimistic about advancing this promising therapeutic option.
I-Mab (Nasdaq: IMAB) announced robust full-year results for 2020, achieving net revenues of RMB 1,542.7 million (US $236.4 million) and corporate profitability. Notably, the company has made significant strides in its clinical pipeline, achieving 18 milestones since its IPO, with three registrational trials currently underway. The New Drug Application for felzartamab (TJ202) is on track for submission in 2021. A global collaboration with AbbVie aims to advance the CD47 antibody lemzoparlimab (TJC4). The company holds a total cash position of RMB 4.8 billion (US $734.1 million), supporting operations through 2023.
I-Mab (Nasdaq: IMAB) will host its 2021 R&D Day with two sessions: a Mandarin session on April 7, 2021, at 14:00 CST, and an English session on April 26, 2021, from 8:00 am to 11:00 am EDT. Key presentations will feature Dr. Jingwu Zang and Dr. Joan Shen, focusing on I-Mab’s pipeline programs and R&D strategy. Investors can join via a live webcast available on the company’s Investor Relations site. I-Mab is transitioning into a fully integrated global biopharma company with over 15 clinical and pre-clinical stage candidates in the immuno-oncology sector.
FAQ
What is the current stock price of I-MAB American Depositary Shares (IMAB)?
What is the market cap of I-MAB American Depositary Shares (IMAB)?
What is I-Mab's core focus?
What are some key products in I-Mab's pipeline?
Where are I-Mab's main operations located?
What recent strategic move has I-Mab made?
What is felzartamab?
Who is I-Mab collaborating with on givastomig?
How does I-Mab fund its operations and research?
What is the significance of the FDA's Breakthrough Therapy designation for felzartamab?
What is I-Mab's approach to drug development?
How can investors stay updated on I-Mab's progress?
